Abstract
Twenty-seven hypertensive patients (23 of whom were black) were treated with hydralazine as their major antihypertensive drug and were followed for evidence of autoimmunity and clinical systemic lupus erythematosus (SLE). Only one patient developed SLE but many, although asymptomatic, had serologic evidence of autoimmunity: antibodies to single- and double-stranded ribonucleic acid (RNA), single-stranded deoxyribonucleic acid (DNA), histones, and lymphocytes. Acetylation phenotype profoundly influenced this response; slow acetylators had a higher incidence and larger amounts of autoantibodies. Antibodies to both types of RNA were a more sensitive index of autoimmunity than antinuclear antibodies. Hydralazine treatment did not alter cell-mediated immune responses. The hydralazine SLE patient had large amounts of autoantibodies that were predominantly IgG, while in the others IgM autoantibodies were predominant. No antibodies, but positive lymphoproliferative responses to hydralazine, were found in half the patients tested.
Citations
Jul 1, 1982·Arthritis and Rheumatism·E V Hess
Jan 1, 1994·Drug Metabolism Reviews·A H Hofstra
Feb 1, 1989·Arthritis and Rheumatism·D M NordstromR L Rubin
Sep 30, 1999·Environmental Health Perspectives·G S CooperJ P Pandey
Mar 8, 2005·Drug Metabolism Reviews·Shufeng ZhouYu-Zong Chen
Jan 1, 1990·Drug Metabolism Reviews·B K Park, N R Kitteringham
Dec 1, 1994·Lupus·L E Adams, A B Mongey
Jan 1, 1994·Drug Metabolism and Drug Interactions·J P Uetrecht
Oct 14, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Y Braun-MoscoviciA M Nahir
Jun 26, 1998·Journal of Gastroenterology and Hepatology·E Jaeckel, M P Manns
Nov 12, 1998·Biochimie·L Weglarz, A Koceva-Chyła
Dec 1, 1993·Chemico-biological Interactions·A H Hofstra, J P Uetrecht
Jul 1, 1985·Clinical Immunology and Immunopathology·R L RubinE M Tan
Mar 2, 2006·Journal of Translational Medicine·Claudia ArceAlfonso Dueñnas-Gonzalez